Company intelligence / Profile preview

Reynolds

Winston-Salem, North Carolina, United Statesreynoldsconsumerproducts.com ↗

Ownership: Private
Development stage: Commercial

Overview

Reynolds American, through its scientific arm "Reynolds Science," conducts research and product development primarily focused on tobacco harm reduction and nicotine science. The company also has a small but active preclinical drug discovery pipeline targeting malaria, Alzheimer’s disease, COVID‑19, and cognition disorders using small molecules and immunostimulants. Its laboratories are ISO/IEC 17025 accredited and follow FDA GLP/GCP standards for nonclinical and clinical studies. No products have reached commercialization in the pharmaceutical space as of now.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: Small moleculeImmunostimulant
Industry: Biotech

Partnerships

Possible collaborations with academic institutions for clinical studies.

Beyond the preview

Go deeper on Reynolds.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reynolds.

Explore the full profile